Showing results (281-290 of 342) with videos related to

Sort By:
Pageof 35
Annals of Hematology|January 22, 2025
Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuriaAustin Kulasekararaj, Robert Brodsky, Hubert Schrezenmeier, et al.
Journal of Inherited Metabolic Disease|February 10, 2018
Hepatocellular carcinoma in Gaucher disease: an international case seriesMartine Regenboog, Laura van Dussen, Joanne Verheij, et al.
American Journal of Hematology|January 23, 2013
Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imigluceraseAri Zimran, Gregory M Pastores, Anna Tylki-Szymanska, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 31, 2020
Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient RegistryYadanar Lwin, Glenn Kennedy, David Gottlieb, et al.
The New England Journal of Medicine|March 17, 2021
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal HemoglobinuriaPeter Hillmen, Jeff Szer, Ilene Weitz, et al.
Neurology. Genetics|May 21, 2021
Occurrence of Amyotrophic Lateral Sclerosis in Type 1 Gaucher DiseaseLais M Oliveira, Tara Rastin, Graeme A M Nimmo, et al.
Blood|September 9, 2011
Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher diseaseAri Zimran, Einat Brill-Almon, Raul Chertkoff, et al.
Internal Medicine Journal|March 7, 2023
The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma AustraliaShirlene Sim, Anna Kalff, Gina Tuch, et al.
Hematology/Oncology and Stem Cell Therapy|June 11, 2019
Special report: Summary of the first meeting of African Blood and Marrow Transplantation (AfBMT) group, Casablanca, Morocco, April 19-21, 2018 held under the auspices of the Worldwide Network for Blood and Marrow Transplantation (WBMT)Mhamed Harif, Daniel Weisdorf, Nicolas Novitzky, et al.
The Lancet. Haematology|September 2, 2022
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trialRégis Peffault de Latour, Jeff Szer, Ilene C Weitz, et al.
Pageof 35